NEW YORK -- The world market for products to treat skin ulcers will grow at nearly 10 percent per year to surpass $5 billion by 2009, according to a new report released today from Kalorama Information. The increasing elderly population, the availability of new therapeutic techniques, and the recent cost-driven focus on wound care management and prevention are driving the growth.
The new study, Wound Care Markets, Volume I: Skin Ulcers, found that certain segments of the market to treat decubitus, neuropathic, arterial and venous ulcers are mature, such as anti-infectives, most skin ulcer management products, and pressure relief devices. However, other segments, such as biological dressings, are still in the infant stages and wide open for development and tremendous growth.
"The opportunities in skin ulcer treatment are very exciting, but the competition is fierce," notes Mary Anne Crandall, the author of the report. "Manufacturers must keep abreast of emerging products, the latest reimbursement changes, and constantly shifting physician usage patterns."
The study examines six broad categories of products-anti-infectives, skin ulcer management products, moist dressings, biological dressings, pressure relief devices, and other miscellaneous treatments-and more than 14 subcategories, including compression dressings and bandages, wound cleaners, debridement products, alginates, films, foams, hydrocolloids, hydrogels, artificial skin products, collagen products, and growth factors.
In addition to a thorough analysis of market size and growth rates through 2009 for each segment and subsegment, the study details competitive market share in each segment and provides a thorough understanding of the clinical and reimbursement environment in which these wound care manufacturers operate.
Source: Kalorama Information
The Latest on CLABSIs and CAUTIs: Evidence-Based Approaches for Infection Prevention
February 27th 2025Health care–associated infections like CLABSIs and CAUTIs threaten patient safety. Learn evidence-based strategies, new technologies, and prevention protocols to reduce these infections and improve outcomes.
Hiding in Plain Sight: The Most Harmful and Costly Hospital-Acquired Infection
February 5th 2025Nonventilator hospital-acquired pneumonia (NV-HAP) is a deadly, overlooked infection impacting patient outcomes. With new diagnostic tools and prevention strategies, hospitals must prioritize oral hygiene to reduce risk.
The Hidden Dangers of Hospital Ventilation: Are We Spreading Viruses Further?
January 31st 2025New research reveals hospital ventilation and air purifiers may unintentionally spread viral particles, increasing infection risks. Infection preventionists must rethink airflow strategies to protect patients and staff.
Alcohol-Based Antiseptics Show Promise for Nasal Decolonization and SSI Prevention
January 23rd 2025A meta-analysis found alcohol-based antiseptics significantly reduce Staphylococcus aureus-related surgical site infections (SSIs), demonstrating efficacy comparable to mupirocin and iodophor, supporting their expanded use in infection prevention strategies.